A new type of anionic high soluble cyclodextrin derivatives
Increase the drug's stability ,solubility ,safety (Include drug molecules to form non-covalent)
Reduce the renal toxicity
Moderate drug's hemolysis
Control the release rate and cover the bad smell
*The following content is generated by AI and is for reference only.
Sulfobutyl ether beta-cyclodextrin sodium, commonly abbreviated as SBE-β-CD or Captisol, is a highly advanced water-soluble derivative of natural beta-cyclodextrin. Its chemical structure features negatively charged sulfobutyl ether groups attached to the glucose units of the parent cyclodextrin ring. The molecular formula is typically represented as C42H60O23SNa4·xH2O, though exact hydration levels vary by batch. It is identified by the CAS number 137058-96-5. This unique anionic character distinguishes it from other cyclodextrin derivatives, providing exceptional stability and solubility in aqueous environments without altering the pH significantly.
The primary application of SBE-β-CD lies in pharmaceutical formulation science, where it serves as a powerful solubilizing agent. Many modern drug candidates suffer from poor aqueous solubility, which limits their bioavailability and therapeutic efficacy. By forming stable inclusion complexes with hydrophobic drug molecules within its central hydrophobic cavity, SBE-β-CD dramatically enhances dissolution rates and systemic absorption. Unlike neutral cyclodextrins, this derivative does not require high concentrations to achieve solubility, reducing potential osmolarity issues in injectable formulations. Furthermore, its safety profile has been extensively validated through rigorous toxicological studies, leading to regulatory approval by the FDA and EMA for various clinical applications.
Beyond solubilization, SBE-β-CD acts as a stabilizer against oxidation and photodegradation, extending the shelf life of sensitive compounds. It is widely utilized in intravenous, oral, ophthalmic, and topical dosage forms. Notable commercial examples include the anticancer agent paclitaxel and various antifungal agents. The negative charge also minimizes non-specific binding to biological membranes, potentially reducing toxicity compared to other excipients. As a versatile excipient, SBE-β-CD continues to play a pivotal role in advancing drug delivery technologies, enabling the development of novel therapeutics that were previously considered undeliverable due to physicochemical limitations. Its ability to improve pharmacokinetic profiles while maintaining patient safety makes it a cornerstone ingredient in modern pharmaceutical innovation.